
Viela Bio, Inc. Revenue 2011-2026 | VIE
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Viela Bio, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 11.7 M | 50 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 50 M | 11.7 M | 30.8 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M | ||
|
Anika Therapeutics
ANIK
|
167 M | $ 14.93 | 0.88 % | $ 219 M | ||
|
Aptorum Group Limited
APM
|
912 K | $ 0.93 | 0.51 % | $ 5.07 M | ||
|
Aquestive Therapeutics
AQST
|
44.5 M | $ 4.14 | 0.36 % | $ 443 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
82 M | $ 8.39 | 4.5 % | $ 230 M | ||
|
Ardelyx
ARDX
|
407 M | $ 6.06 | 1.94 % | $ 1.46 B | ||
|
argenx SE
ARGX
|
36.4 M | $ 749.68 | 0.44 % | $ 25 B | ||
|
Arcutis Biotherapeutics
ARQT
|
376 M | $ 23.93 | 1.27 % | $ 3.04 B | ||
|
Arvinas
ARVN
|
263 M | $ 11.36 | 4.7 % | $ 805 M | ||
|
I-Mab
IMAB
|
88 M | - | - | $ 866 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
829 M | $ 61.99 | 1.57 % | $ 8.29 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B | ||
|
Assembly Biosciences
ASMB
|
72.3 M | $ 29.09 | 0.28 % | $ 326 M | ||
|
Actinium Pharmaceuticals
ATNM
|
90 K | $ 1.13 | 15.26 % | $ 35.3 M | ||
|
Atossa Therapeutics
ATOS
|
1.76 K | $ 5.19 | -3.36 % | $ 44.7 M | ||
|
Atara Biotherapeutics
ATRA
|
121 M | $ 5.0 | 0.2 % | $ 62.7 M | ||
|
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
77.1 M | $ 16.05 | 2.79 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
75.4 M | $ 1.41 | -0.35 % | $ 375 M | ||
|
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | ||
|
Axon Enterprise
AXON
|
2.08 B | $ 411.97 | -0.2 % | $ 31.2 B | ||
|
Aytu BioScience
AYTU
|
66.4 M | $ 2.65 | -1.12 % | $ 16.6 M | ||
|
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - | ||
|
BioCardia
BCDA
|
58 K | $ 1.18 | -1.67 % | $ 7.87 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
451 M | $ 9.59 | 6.26 % | $ 1.98 B | ||
|
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
463 M | $ 9.46 | -3.47 % | $ 612 M | ||
|
BioLineRx Ltd.
BLRX
|
28.9 M | $ 2.32 | 4.98 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
3.22 B | $ 56.04 | 0.96 % | $ 10.7 B | ||
|
BioNTech SE
BNTX
|
482 M | $ 91.64 | 0.5 % | $ 27.2 B | ||
|
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | ||
|
BioXcel Therapeutics
BTAI
|
642 K | $ 1.18 | -0.42 % | $ 14.4 M | ||
|
Burford Capital Limited
BUR
|
330 M | $ 4.5 | 8.57 % | $ 683 M |